Amphista Therapeutics to Showcase Three Targeted Glue™ Degrader Programs at AACR 2026
Event summary
- Amphista Therapeutics will present three programs at the AACR 2026 Annual Meeting, including an invited talk on AMX-883, its BRD9 clinical candidate for AML treatment.
- The company will detail the development of SMARCA2 selective Targeted Glue™ degraders for SMARCA4-deficient tumors, showcasing >95% degradation efficiency within 4 hours.
- Amphista will also present on TEAD Targeted Glue™ degraders for mesothelioma and NSCLC, leveraging an aldehyde-mediated degron mechanism.
- Presentations will take place on April 20 and 21, 2026, in San Diego.
The big picture
Amphista Therapeutics is positioning itself as a leader in next-generation targeted protein degradation, focusing on non-cereblon/non-VHL mechanisms. The company’s presentations at AACR 2026 highlight its progress in developing selective degraders for difficult-to-treat cancers, aligning with the broader industry shift toward precision oncology. With backing from major investors, Amphista’s ability to advance its pipeline will be critical in determining its long-term competitive edge.
What we're watching
- Clinical Validation
- Whether AMX-883 can demonstrate efficacy in AML patients, particularly those with karyotype-independent profiles.
- Competitive Positioning
- How Amphista’s SMARCA2 and TEAD degraders differentiate from existing and emerging therapies in NSCLC and mesothelioma.
- Investor Interest
- The pace at which Amphista can translate preclinical data into clinical milestones to attract further funding.
Our editorial coverage:
Related topics